Xilio Therapeutics (XLO) Research & Development (2020 - 2026)

Xilio Therapeutics has disclosed Research & Development across 7 years of filings, most recently posting $19.8 million for Q1 2026.

• Research & Development for Q1 2026 came in at $19.8 million, up 139.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $67.6 million (up 73.0% YoY), and the FY2025 annual result was $56.0 million, up 35.98% from the prior year.
• Research & Development came in at $19.8 million for Q1 2026 at Xilio Therapeutics, up from $18.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $19.8 million in Q1 2026 to a low of $8.3 million in Q1 2025.
• The 5-year median for Research & Development is $13.2 million (2023), against an average of $13.4 million.
• Across the five-year window, Research & Development tumbled 35.53% in 2024 and soared 139.92% in 2026, its largest moves.
• Xilio Therapeutics' Research & Development stood at $15.0 million in 2022, then dropped by 21.74% to $11.7 million in 2023, then fell by 24.71% to $8.8 million in 2024, then jumped by 105.09% to $18.1 million in 2025, then gained by 9.44% to $19.8 million in 2026.
• The last three Research & Development figures came in at $19.8 million (Q1 2026), $18.1 million (Q4 2025), and $14.3 million (Q3 2025), per Business Quant data.